F3 and neoplasm: Specifically, fibrin deposition, initiated through tumor-expressed tissue factor (TF), forms dense “fibrin clot shields” that physically impede cytotoxic immune cell binding and hinder drug penetration, thereby reducing MMC-induced tumor cell clearance [54].